SCHEMBL5093607

SCHEMBL5093607

C=CC(=O)c1cccc2c1S(=O)(=O)NC2=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 10/20 0.45
CA9 Q16790 10/20 0.45
CA2 P00918 9/20 0.45
CA7 P43166 7/20 0.45
CA1 P00915 6/20 0.45
CA4 P22748 2/20 0.45
KDM4E B2RXH2 1/20 0.45
USP2 O75604 1/20 0.45
LMNA P02545 1/20 0.45
BCHE P06276 1/20 0.45
CA6 P23280 1/20 0.45
CA5A P35218 1/20 0.45
KMT2A Q03164 1/20 0.45
CA14 Q9ULX7 1/20 0.45
CA5B Q9Y2D0 1/20 0.45
CYP2D6 P10635 1/20 0.33
TSHR P16473 1/20 0.33
AKT1 P31749 1/20 0.33
LIG1 P18858 1/20 0.33
PDE7A Q13946 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1081860 0.81 CA12 (0.50) CA12CA9CA2CA7CA1
SCHEMBL10656700 0.80 CA12 (0.49) CA12CA9CA2CA7CA1
SCHEMBL10741433 0.78 TYMS (0.43) CA12CA9CA2CA7CA1
SCHEMBL8995896 0.78 CA12 (0.44) CA12CA9CA2CA7CA1
SCHEMBL362202 0.77 CYP3A4 (0.51) KDM4ELMNABCHEKMT2ACYP2D6
SCHEMBL19586659 0.75 CA12 (0.43) CA12CA9CA2CA7CA1
SCHEMBL7763714 0.75 CA12 (0.44) CA12CA9CA2CA7CA1
SCHEMBL1661224 0.74 CA12 (0.46) CA12CA9CA2CA7CA1
SCHEMBL10734721 0.74 CA12 (0.42) CA12CA9CA2CA7CA1
SCHEMBL6739070 0.72 CA12 (0.41) CA12CA9CA2CA7CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1649037-A4 IMMOBILIZATION OF OLIGONUCLEOTIDES AND PROTEINS IN SUGAR-CONTAINING HYDROGELS US GOV SEC NAVY (US) 2008-04-23 EP claimed
US-20060246499-A1 Sugar-containing hydrogel for immobilization NAVY, U.S.A. AS REPRESENTED BY THE SECRETARY OF THE, THE 2006-11-02 US claimed
EP-1649037-A2 IMMOBILIZATION OF OLIGONUCLEOTIDES AND PROTEINS IN SUGAR-CONTAINING HYDROGELS The Government of the United States of America as represented by the Secretary of the Navy (US) 2006-04-26 EP claimed
WO-2005017180-A2 IMMOBILIZATION OF OLIGONUCLEOTIDES AND PROTEINS IN SUGAR-CONTAINING HYDROGELS THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 2005-02-24 WO claimed
US-20050019884-A1 Immobilization of oligonucleotides and proteins in sugar-containing hydrogels NAVY, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE 2005-01-27 US claimed
EP-0237131-B1 PROCESS FOR THE PREPARATION OF WATER-SOLUBLE SACCHARIDE POLYMERS SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1991-07-24 EP claimed
US-4701494-A USING (METH) ACRYLOYL MONO- AND DISACCHARIDES, AN AZO FREE RADICAL CATALYST AND LIMITED AMOUNT OF MONOMER IN AQUEOUS SOLUTION SHELL OIL COMPANY (US) 1987-10-20 US claimed
US-5480790-A PROTEINS ARE COVALENTLY BOUND TO POLYVINYLSACCHARIDE VIA A SACCHARIDE RESIDUE; PROTEIN-SACCHARIDE COMPLEXES SUCH AS DEXTRAN-T-40-ALPHA-GLUCOSIDASE AND GLUTAMATE DEHYDROGENASE POLYVINYLSACCHARIDE; ENZYME ANALYSIS; TEST KIT BOEHRINGER MANNHEIM GMBH (DE) 1996-01-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050019884-A1 Immobilization of oligonucleotides and proteins in sugar-containing hydrogels PHAX, SLC2A4, CD44 CA12 1202/4885CA9 1613/4885CA2 1638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.